Cutler Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Cutler Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30	Closed	-$3K	–	4412
2023 Q1	$3K	Sell	30 -6,290	-100%	-$724K	﹤0.01%	3056
2022 Q4	$695K	Buy	+6,320	New	+$410K	0.06%	351

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Cutler Group's RXDX Position: Q2 2023 in Review

Cutler Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 30 shares — an estimated $3K sold.

Cutler Group first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $695K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Cutler Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Cutler Group sold 30 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $3K.
Cutler Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Cutler Group's Prometheus Biosciences, Inc. Common Stock position peaked at $695K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.